REGENXBIO sues Aldevron for infringement of patented host cells used to make DNA for gene therapy applications
Clients REGENXBIO Inc.
Jones Day represents REGENXBIO Inc. in a patent infringement lawsuit brought against Aldevron LLC claiming that without authorization, Aldevron used and manufactured cultured host cells containing recombinant nucleic acid molecules with sequences encoding AAV8 capsid protein(s) and a heterologous non-AAV sequence. These cultured host cells are used to replicate plasmid DNA used to make capsid proteins to package genes for gene therapy applications.
REGENXBIO Inc., et al. v. Aldevron LLC, No. 3-20-cv-00171 (D.N.D.)